FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrilic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer

Thumbnail
2019
3339.pdf (200.3Kb)
Authors
Jovanović, Dragana
Roksandić-Milenković, Marina
Kotur-Stevuljević, Jelena
Ceriman, Vesna
Vukanić, Ivana
Samardžić, Natalija
Popević, Spasoje
Ilić, Branislav
Gajić, Milija
Simon, Marioara
Simon, Ioan
Spasojević-Kalimanovska, Vesna
Belić, Milica
Mirkov, Damjan
Šumarac, Zorica
Milenković, Vladislav
Article (Published version)
Metadata
Show full item record
Abstract
Background: The objective of this prospective study was to evaluate whether soluble programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) and serum amyloid A1 (SAA1) are potential diagnostic, predictive or prognostic biomarkers in lung cancer. Methods: Lung cancer patients (n=115) with advanced metastatic disease, 101 with non-small cell lung cancer, NSCLC (77 EGFR wild-type NSCLC patients on chemotherapy, 15 EGFR mutation positive adenocarcinoma patients, 9 patients with mPD-L1 Expression >= 50% NSCLC - responders to immunotherapy), and 14 patients with small cell lung cancer (SCLC) were examined. ELISA method was used to determine sPD-L1 and SAA1 concentrations in patients' plasma. Results: Significantly higher blood concentrations of sPD-L1 and SAA1 were noted in lung cancer patients compared with a healthy control group. In PD-L1 + NSCLC patients, a significantly higher sPD-L1 level was noticed compared to any other lung cancer subgroup, as well as the highest average... SAA1 value compared to other subgroups. Conclusions: It seems that sPD-1/PD-L1 might be a potential biomarker, prognostic and/or predictive, particularly in patients treated with immunotherapy. Serum amyloid A1 has potential to act as a good predictor of patients' survival, as well as a biomarker of a more advanced disease, with possibly good capability to predict the course of disease measured at different time points.

Keywords:
sPD-L1 / serum amyloid A1 / biomarker / PD-L1 positive NSCLC
Source:
Journal of Medical Biochemistry, 2019, 38, 3, 332-341
Publisher:
  • Društvo medicinskih biohemičara Srbije, Beograd i Versita
Projects:
  • Clinical and epidemiological study of adverse events in hospital patients (RS-175046)

DOI: 10.2478/jomb-2018-0036

ISSN: 1452-8258

PubMed: 31156344

WoS: 000468363100011

Scopus: 2-s2.0-85057603105
[ Google Scholar ]
6
5
URI
http://farfar.pharmacy.bg.ac.rs/handle/123456789/3341
Collections
  • Radovi istraživača / Researchers’ publications
Institution
Pharmacy

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceInstitutionsAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB